drugset / Trial / NCT03303144

Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

NCT03303144

Phase 1/2 Completed 27 enrolled Rockwell Medical Technologies, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The main purpose is to establish the equivalence of Triferic iron administered via dialysate into the arterial blood line and into the venous blood line

Timeline

Start
2017-10-01
Primary completion
2017-12-28
Completion
2017-12-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Triferic Other / unclassified 6.5 mg Other